Holen Sie sich die Stockscreener-App
3.15
1.87%
-0.06
Schlusskurs vom Vortag:
$3.21
Offen:
$3.18
24-Stunden-Volumen:
352.61K
Relative Volume:
0.60
Marktkapitalisierung:
$47.32M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.47M
KGV:
-0.5093
EPS:
-6.1852
Netto-Cashflow:
$-52.33M
1W Leistung:
-4.83%
1M Leistung:
-38.83%
6M Leistung:
-47.59%
1J Leistung:
-85.11%
1-Tages-Spanne:
$3.10
$3.259
1-Wochen-Bereich:
$3.10
$3.5199
52-Wochen-Spanne:
$2.265
$26.05
Jasper Therapeutics Inc Stock (JSPR) Company Profile
Firmenname
Jasper Therapeutics Inc
Sektor
Branche
Telefon
(650) 549-1400
Adresse
2200 BRIDGE PKWY SUITE #102, REDWOOD CITY
Vergleichen Sie JSPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JSPR
Jasper Therapeutics Inc
|
3.15 | 49.72M | 0 | -64.47M | -52.33M | -6.1852 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Jasper Therapeutics Inc Stock (JSPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-08 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2025-07-08 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-07-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-07-07 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-09-09 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-07-08 | Eingeleitet | BTIG Research | Buy |
| 2024-06-27 | Eingeleitet | Stifel | Buy |
| 2024-05-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-03 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-03-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-08-11 | Eingeleitet | CapitalOne | Overweight |
| 2022-02-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Eingeleitet | Credit Suisse | Outperform |
| 2021-10-21 | Eingeleitet | William Blair | Outperform |
| 2021-10-20 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-13 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Jasper Therapeutics Inc Aktie (JSPR) Neueste Nachrichten
Jasper Therapeutics Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What drives Jasper Therapeutics Inc. Equity Warrant stock priceFree Market Volatility Navigation Tips - jammulinksnews.com
Is Jasper Therapeutics Inc. Equity Warrant a good long term investmentFree Stock Market Return Analysis - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. stockMarket-beating performance - jammulinksnews.com
What analysts say about Jasper Therapeutics Inc. Equity Warrant stockUnmatched profit growth - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc.JSPR - PR Newswire
Jasper Therapeutics Inc. Equity Warrant Stock Analysis and ForecastDynamic portfolio growth - printweek.in
Is Jasper Therapeutics Inc. a good long term investmentJaw-dropping returns - Autocar Professional
What drives Jasper Therapeutics Inc. stock pricePhenomenal capital appreciation - printweek.in
Trading (JSPR) With Integrated Risk Controls - news.stocktradersdaily.com
Layoff Tracker: Following Challenges With DMD Therapy, Sarepta Will Cut 500 Employees - BioSpace
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - GlobeNewswire Inc.
Jasper Therapeutics’ SWOT analysis: briquilimab stock faces pivotal moment - Investing.com
Finance Watch: Karyopharm Cuts Jobs In Cash Crunch; Pacira’s Layoffs Attributed To Efficiency - insights.citeline.com
Bay Area biotech company's drug mishap leads to dozens of layoffs - SFGATE
HC Wainwright Issues Positive Estimate for JSPR Earnings - Defense World
Jasper Therapeutics' Data Crisis and the Investor's Dilemma: Fraud or Unfortunate Setback? - AInvest
Jasper Therapeutics price target lowered to $12 from $70 at Citizens JMP - MSN
Redwood City's Jasper Therapeutics Valuation Tumbles Amid Clinical Trial Setbacks and Layoffs - Hoodline
Jasper Therapeutics shares fall 1.99% after-hours as Schall Law Firm investigates securities law violations. - AInvest
JSPR Investors Have Opportunity to Join Jasper Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Jasper Therapeutics stock holds Market Outperform rating at JMP despite setback - Investing.com Canada
Jasper Therapeutics Announces Major Corporate Reorganization - The Globe and Mail
BMO Capital Markets Reaffirms “Market Perform” Rating for Jasper Therapeutics (NASDAQ:JSPR) - Defense World
Jasper Therapeutics cuts workforce by 50% to focus on urticaria programs - Investing.com South Africa
Where are the Opportunities in (JSPR) - news.stocktradersdaily.com
Peninsula biotech Jasper Therapeutics to lay off half its staff as cash runs lowSan Francisco Business Times - The Business Journals
Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway - MarketScreener
Jasper Therapeutics: A Strategic Gamble on Capital Efficiency and Clinical Focus Ahead of Pivotal Data - AInvest
Jasper Therapeutics falls after halting clinical programs - TradingView
Jasper Therapeutics Announces 50% Workforce Reduction And Strategic Refocus On Chronic Urticaria Programs To Extend Cash Runway And Advance Briquilimab Development - 富途牛牛
Jasper Therapeutics Announces 50% Workforce Reduction and Leadership Change to Enhance Focus on Chronic Urticaria Programs - Nasdaq
Jasper Therapeutics Slashes Workforce by Half, Pivots All Resources to Promising Urticaria Treatment - Stock Titan
Finanzdaten der Jasper Therapeutics Inc-Aktie (JSPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):